Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis

European Journal of Cancer

Volumn 51, Issue 7, 2015, Pages 800-807

  Petrelli, Fausto ^a   Pietrantonio, Filippo ^b   Cremolini, Chiara ^c   Di Bartolomeo, Maria ^b   Coinu, Andrea ^a   Lonati, Veronica ^a   De Braud, Filippo ^b   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Colorectal cancer; Early tumour shrinkage; First line therapy; Overall survival; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; PANITUMUMAB; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DISEASE MARKER; DRUG RESPONSE; EARLY TUMOR SHRINKAGE; HUMAN; META ANALYSIS; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; ADJUVANT THERAPY; COLORECTAL NEOPLASMS; DRUG EFFECTS; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84927513911     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.02.011     Document Type: Review

References (26)

1. V. Heinemann, L.F. von Weikersthal, and T. Decker FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 10 2014 1065 1075
2. F. Petrelli, and S. Barni Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer Ann Oncol 24 1 2013 186 192
3. M. Ronot, M. Bouattour, and J. Wassermann Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib Oncologist 19 4 2014 394 402
4. S. Oudard, R. Thiam, and L.S. Fournier Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study Eur J Cancer 48 10 2012 1512 1518
5. K.M. Krajewski, Y. Franchetti, and M. Nishino 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study Oncologist 19 5 2014 507 514
6. P.A. Tang, S.M. Bentzen, and E.X. Chen Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J Clin Oncol 25 29 2007 4562 4568
7. M. Buyse, P. Thirion, and R.W. Carlson Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis - Meta-Analysis Group in Cancer Lancet 356 9227 2000 373 378
8. S. Stintzing, D. Modest, and L. Fisher von Weikersthal et al. Independent radiological evaluation of objective response rate, early tumour shrinkage, and depth of response in the FIRE-3 study: analysis in the final RAS evaluable population Ann Oncol 25 Suppl. 4 2014 LBA11
9. C. Cremolini, F. Loupakis, and S. Lonardi Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: results from the phase III TRIBE trial J Clin Oncol 32 Suppl. 3 2014 [abstr. 521]
10. H. Piessevaux, M. Buyse, and M. Schlichting Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 31 30 2013 3764-37
11. L.V. Hedges, and T.D. Pigott The power of statistical tests in meta-analysis Psychol Methods 6 2000 203 217
12. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
13. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
14. T. Burzykowski, G. Molenberghs, and M. Buyse The evaluation of surrogate endpoints 2005 Springer New York, NY
15. C. Giessen, R.P. Laubender, and L. Fischer von Weikersthal Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial Cancer Sci 104 6 2013 718 724
16. D.P. Modest, R.P. Laubender, and S. Stintzing Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial Acta Oncol 52 5 2013 956 962
17. C. Suzuki, L. Blomqvist, and A. Sundin The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy Ann Oncol 23 4 2012 948 954
18. J. Ichante, A. Adenis, and D. Malka Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab J Clin Oncol 29 Suppl. 2011 [abstr e14041]
19. J. Douillard, S. Siena, and J. Tabernero Understanding the value of response and early tumour shrinkage (ETS) in pts with wt KRAS mCRC treated with panitumumab (P) plus folfox (F) Ann Oncol 23 Suppl. 9 2012 190
20. W. Zhang, S. Cai, and W. Li Quantitative analyses of early tumor shrinkage on clinical outcome in an open, non-randomized, multicenter phase ii clinical trial (clime study) Ann Oncol 25 Suppl. 4 2014 [abstr. 545P]
21. D.W. Sommeijer, Q. Shi, and E.D. Saad Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): an ARCAD study with individual patient data (IPD) on 10,962 pts J Clin Oncol 32 Suppl. 5 2014 [abstr. 3538]
22. M. Buyse, T. Burzykowski, and K. Carroll Progression-free survival is a surrogate for survival in advanced colorectal cancer J Clin Oncol 25 33 2007 5218 5224
23. Q. Shi, A. De Gramont, and M.E. Buyse Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: findings from the 16,700 patients (pts) ARCAD database J Clin Oncol 31 Suppl. 2013 [abstr. 3533]
24. R. Bruno, F. Mercier, and L. Claret Evaluation of tumor size response metrics to predict survival in oncology clinical trials Clin Pharmacol Ther 95 4 2014 386 393
25. T.G. Karrison, M.L. Maitland, and W.M. Stadler Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer J Natl Cancer Inst 99 19 2007 1455 1461 Erratum. In: J Natl Cancer Inst 2007;99(23):1819
26. E. Coart, E.D. Saad, and Q. Shi Trial-level association between response-based endpoints and progression-free/overall survival in 1st-line therapy for metastatic colorectal cancer in the ARCAD database J Clin Oncol 33 Suppl. 3 2015 [abstr. 666]